The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives; namely, ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

Draft guidance from reimbursement authority NICE has recommended use of the artificial intelligence technologies – Aidoc ...

Developing new biomarker assays is highly specialised work. It requires careful screening of antibody pairs, sensitivity and ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management.

At ASCO 2025, Johnson & Johnson contributed more than 70 abstracts, reflecting the depth of their oncology portfolio, and commitment to redefining what’s possible for a wide range of solid tumour and ...

From dissecting clinical updates to identifying novel targets beyond NLRP3, this summit brings together the brightest minds transforming the field of innate immunity and inflammation.

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...